Search
Now showing items 391-396 of 396
Unravelling the mechanisms of acquired immunomodulatory drug resistance in multiple myeloma
(Institute of Cancer Research (University Of London), 2023-12-01)
Immunomodulatory drugs (IMiDs) are a cornerstone of multiple myeloma
treatment and newer cereblon E3 ligase modulating drugs (CELMoDs) are in
clinical trials. However, a major barrier to improving patient outcomes is ...
Drug delivery across the blood-brain barrier using short-pulse focused ultrasound and microbubbles for the treatment of diffuse intrinsic pontine glioma
(Institute of Cancer Research (University Of London), 2023-09-01)
The blood-brain barrier (BBB) prevents unwanted substances from entering the brain, but also blocks entry of therapeutic agents, posing difficulties for treating brain cancers such as diffuse intrinsic pontine glioma (DIPG) ...
Determination of Ligand-Binding Affinity (Kd) Using Transverse Relaxation Rate (R2) in the Ligand-Observed 1H NMR Experiment and Applications to Fragment-Based Drug Discovery.
(AMER CHEMICAL SOC, 2023-08-10)
High hit rates from initial ligand-observed NMR screening can make it challenging to prioritize which hits to follow up, especially in cases where there are no available crystal structures of these hits bound to the target ...
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.
(AMER ASSOC CANCER RESEARCH, 2023-06-02)
UNLABELLED: Understanding the evolutionary pathways to metastasis and resistance to immune-checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here, we present the most comprehensive intrapatient ...
The role of systemic therapy in paediatric cutaneous melanoma: a review
(AME PUBLISHING COMPANY, 2023-11-30)
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
(ELSEVIER, 2023-11-01)
BACKGROUND: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative ...